Gsk (GSK) Cash from Financing Activities (2009 - 2026)

Gsk (GSK) has 18 years of Cash from Financing Activities data on file, last reported at -$2.5 billion in Q3 2026.

• For the quarter ending Q3 2026, Cash from Financing Activities changed N/A year-over-year to -$2.5 billion; the trailing twelve-month figure through Sep 2026 stood at -$3.1 billion (changed N/A YoY), and the FY2025 full-year result was -$4.9 billion, up 18.86% from the prior year.
• Cash from Financing Activities was -$2.5 billion for Q3 2026 at Gsk, down from $366.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.1 billion in Q1 2025 to a low of -$6.6 billion in Q4 2022.
• A 5-year average of -$1.7 billion and a median of -$1.5 billion in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 852.69% in 2024 and surged 180.37% in 2025, its largest moves.
• Gsk's Cash from Financing Activities stood at -$6.6 billion in 2022, then jumped by 94.57% to -$356.2 million in 2023, then sank by 852.69% to -$3.4 billion in 2024, then surged by 40.66% to -$2.0 billion in 2025, then fell by 25.14% to -$2.5 billion in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$2.5 billion in Q3 2026, $366.7 million in Q1 2026, and -$2.0 billion in Q4 2025.